Does anyone reckon that NRPH and SHPGY have fallen out over NRP104? NRPH have just raised $150m through a convertible bond issue and have said that the majority of the money will be spent on marketing NRP104. They have also exercised their option to co-market NRP104 with Shire. This all seems strange to me. Maybe NRPH thinks that Shire will perhaps market their own products in competition with NRP104. Any thoughts?
I wonder how the co-promote is going to work? Is there a length of time they will co-promote it? Shire will eventually be promoting four adhd products on the market not including nrp104. XR2, adderall patch, a non-stim, and daytrana. maybe nrph thinks that these four products will compete with nrp104? I don't know why they just don't leave the promoting in the hands of shire. Shire knows ADHD and they're sales force knows ADHD. Will shire not invest as much in promoting nrp104 now that nrph is involved? I guess nrph has a reason behind this move but I sure can't figure it out.